Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation

References

• Takikawa O, Yoshida R, Kido R. Tryptophan degradation in mice initiated by indoleamine 2,3-Dioxygenase. J Biol Chem 1986;261:3648–53.
   PubMed Web of Science ®Google Scholar
• Paul S, Roy A, Deka SJ, et al. Nitrobenzofurazan derivatives of N'-hydroxyamidines as potent inhibitors of indoleamine-2,3-dioxygenase 1. Eur J Med Chem 2016;121:364–75.
   PubMed Web of Science ®Google Scholar
• Hayaishi O. Properties and function of indoleamine 2,3-dioxygenase. J Biochem 1976;79:13P–21P.
   PubMed Web of Science ®Google Scholar
• Löb S, Königsrainer A, Zieker D, et al. IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother 2009;58:153–7.
   PubMed Web of Science ®Google Scholar
• Croitoru-Lamoury J, Lamoury FMJ, Caristo M, et al. Interferon-γ regulates the proliferation and differentiation of mesenchymal stem cells via activation of indoleamine 2,3 dioxygenase (IDO). PLoS One 2011;6:e14698.
   PubMed Web of Science ®Google Scholar
• Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004;4:762–74.
   PubMed Web of Science ®Google Scholar
• Uyttenhove C, Pilotte L, Theate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003;9:1269–74.
   PubMed Web of Science ®Google Scholar
• Munn DH, Mellor AL. IDO and tolerance to tumors. Trends Mol Med 2004;10:15–8.
   PubMed Web of Science ®Google Scholar
• Zheng X, Koropatnick J, Li M, et al. Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference. J Immunol 2006;177:5639–46.
   PubMed Web of Science ®Google Scholar
• Muller AJ, DuHadaway JB, Chang MY, et al. Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion. Cancer Immunol Immunother 2010;59:1655–63.
   PubMed Web of Science ®Google Scholar
• Crosignani S, Bingham P, Bottemanne P, et al. Discovery of a novel and selective indoleamine 2,3-dioxygenase (IDO-1) inhibitor 3-(5-fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and its characterization as a potential clinical candidate. J Med Chem 2017;60:9617–29.
   PubMed Web of Science ®Google Scholar
• Hou DY, Muller AJ, Sharma MD, et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 2007;67:792–801.
   PubMed Web of Science ®Google Scholar
• Yue EW, Douty B, Wayland B, et al. Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. J Med Chem 2009;52:7364–7.
   PubMed Web of Science ®Google Scholar
• Liu X, Newton RC, Friedman SM, et al. Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy. Curr Cancer Drug Targets 2009;9:938–52.
   PubMed Web of Science ®Google Scholar
• Godin-Ethier J, Hanafi LA, Piccirillo CA, et al. Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res 2011;17:6985–91.
   PubMed Web of Science ®Google Scholar
• Spranger S, Horton B, Koblish HK, et al. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer 2014;2:3.
   PubMedGoogle Scholar
• Muller AJ, Duhadaway JB, Donover PS, et al. Inhibition of indoleamine 2,3-dioxygenase, an immune-regulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005;11:312–9.
   PubMed Web of Science ®Google Scholar
• Pan L, Zheng Q, Chen Y, et al. Design, synthesis and biological evaluation of novel naphthoquinone derivatives as IDO1 inhibitors Design, synthesis and biological evaluation of novel naphthoquinone derivatives as IDO1 inhibitors. Eur J Med Chem 2018;157:423–36.
   PubMed Web of Science ®Google Scholar
• Sheridan C. IDO inhibitors move center stage in immuno-oncology. Nat Biotechnol 2015;33:321–2.
   PubMed Web of Science ®Google Scholar
• Available from: <http://clinicaltrials.gov/show/NCT01191216> [last accessed 27 Feb 2017].
   Google Scholar
• Available from: <http://clinicaltrials.gov/show/NCT00567931> [last accessed 27 Feb 2017].
   Google Scholar
• Cady SG, Sono M. 1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Arch Biochem Biophys 1991;291:326–33.
   PubMed Web of Science ®Google Scholar
• Available from: https://integrity.thomsonpharma.com/integrity/xmlxsl/pk_qcksrch.show_records?sessionID=1&history=&query=GDC0919&abbreviation=PRO&language=en.
   Google Scholar
• Mautino MR, Jaipuri FA, Waldo J, et al. NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy. Cancer Res 2013;73:491.
   Google Scholar
• Yue EW, Sparks R, Polam P, et al. INCB24360 (Epacadostat), a highly potent and selective indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor for immuno-oncology. ACS Med Chem Lett 2017;8:486–91.
   PubMed Web of Science ®Google Scholar
• Tumang J, Gomes B, Wythes M, et al. PF-06840003: a highly selective IDO-1 inhibitor that shows good in vivo efficacy in combination with immune checkpoint inhibitors. 107th Annu Meet Am Assoc Cancer Res (AACR); 2016 April 16–20; New Orleans.
   Google Scholar
• Balog A. Discovery of a selective inhibitor of indoleamine-2,3-dioxygenase for use in the therapy of cancer. 253rd Am Chem Soc (ACS) Natl Meet; 2017 April 2–6; San Francisco.
   Google Scholar
• Molinier-Frenkel V, Castellano F. Immunosuppressive enzymes in the tumor microenvironment. FEBS Lett 2017;591:3135–57.
   PubMed Web of Science ®Google Scholar
• Qian S, Zhang M, Chen QL, et al. IDO as a drug target for cancer immunotherapy: recent developments in IDO inhibitors discovery. RSC Adv 2016;6:7575–81.
   Web of Science ®Google Scholar
• Zhang Y, Yang S, Jiao Y, et al. An integrated virtual screening approach for VEGFR-2 inhibitors. J Chem Inf Model 2013;53:3163–77.
   PubMed Web of Science ®Google Scholar
• Drwal MN, Griffith R. Combination of ligand- and structure-based methods in virtual screening. Drug Discov Today Technol 2013;10:e395–401.
   PubMedGoogle Scholar
• Tian S, Sun H, Li Y, et al. Development and evaluation of an integrated virtual screening strategy by combining molecular docking and pharmacophore searching based on multiple protein structures. J Chem Inf Model 2013;53:2743–56.
   PubMed Web of Science ®Google Scholar
• Molecular Operating Environment (MOE). Montreal, QC: Chemical Computing Group Inc.; 2013.
   Google Scholar
• Liem SY, Popelier PL. The hydration of serine: multipole moments versus point charges. Phys Chem Chem Phys 2014;16:4122–34.
   PubMed Web of Science ®Google Scholar
• Sun HP, Xu XL, Wu XW, et al. Discovery and design of tricyclic scaffolds as protein kinase CK2 (CK2) inhibitors through a combination of shape-based virtual screening and structure-based molecular modification. J Chem Inf Model 2013;53:2093–102.
   PubMed Web of Science ®Google Scholar
• Sugimoto H, Oda S, Otsuki T, et al. Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. Proc Natl Acad Sci USA 2006;103:2611–6.
   PubMed Web of Science ®Google Scholar
• Tojo S, Kohno T, Tanaka T, et al. Crystal structures and structure activity relationships of imidazothiazole derivatives as IDO1 inhibitors. ACS Med Chem Lett 2014;5:1119–23.
   PubMed Web of Science ®Google Scholar
• Peng YH, Ueng SH, Tseng CT, et al. Important hydrogen bond networks in indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor design revealed by crystal structures of imidazoleisoindole derivatives with IDO1. J Med Chem 2016;59:282–93.
   PubMed Web of Science ®Google Scholar
• GOLD, version 5.1. Cambridge: CCDC. Available from: www.ccdc.cam.ac.uk; September 6, 2011.
   Google Scholar
• Jones G, Willett P, Glen RC, et al. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997;267:727–48.
   PubMed Web of Science ®Google Scholar
• Wu G, Robertson DH, Brooks CL, et al. Detailed analysis of grid-based molecular docking: a case study of CDOCKER-A CHARMm-based MD docking algorithm. J Comput Chem 2003;24:1549–62.
   PubMed Web of Science ®Google Scholar
• Labute P. The generalized born/volume integral implicit solvent model: estimation of the free energy of hydration using London dispersion instead of atomic surface area. J Comput Chem 2008;29:1693–8.
   PubMed Web of Science ®Google Scholar
• Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 2009;30:2785–91.
   PubMed Web of Science ®Google Scholar
• Glide, version 6.6. New York, NY: Schrödinger, LLC; 2015.
   Google Scholar
• Kirton SB, Murray CW, Verdonk ML, et al. Prediction of binding modes for ligands in the cytochromes P450 and other heme-containing proteins. Proteins 2005;58:836–44.
   PubMed Web of Science ®Google Scholar
• Li X, Bian JL, Wang N, et al. Novel naphtho[2,1-d]oxazole-4,5-diones as NQO1 substrates with improved aqueous solubility: design, synthesis, and in vivo antitumor evaluation. Bioorg Med Chem 2016;24:1006–13.
   PubMed Web of Science ®Google Scholar
• Avdeef A, Tsinman O. Miniaturized rotating disk intrinsic dissolution rate measurement: effects of buffer capacity in comparisons to traditional wood’s apparatus. Pharm Res 2008;25:2613–27.
   PubMed Web of Science ®Google Scholar
• Sun HP, Jia JM, Jiang F, et al. Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3-d]pyrimidines core through shape-based screening. Eur J Med Chem 2014;79:399–412. − 
   PubMed Web of Science ®Google Scholar
• Fuchs JE, Spitzer GM, Javed A, et al. Minor groove binders and drugs targeting proteins cover complementary regions in chemical shape space. J Chem Inf Model 2011;51:2223–32.
   PubMed Web of Science ®Google Scholar
• Hawkins PCD, Skillman AG, Nicholls A. Comparison of shape-matching and docking as virtual screening tools. J Med Chem 2007;50:74–82.
   PubMed Web of Science ®Google Scholar
• Kirchmair J, Distinto S, Markt P, et al. How to optimize shape-based virtual screening: choosing the right query and including chemical information. J Chem Inf Model 2009;49:678–92.
   PubMed Web of Science ®Google Scholar
• Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem 2010;53:2719–40.
   PubMed Web of Science ®Google Scholar
• OMEGA, 2.4.6. Santa Fe, NM: OpenEye Scientific Software; 2012.
   Google Scholar
• Xue L, Godden JW, Stahura FL, et al. Design and evaluation of a molecular fingerprint involving the transformation of property descriptor values into a binary classification scheme. J Chem Inf Comput Sci 2003;43:1151–7.
   PubMedGoogle Scholar
• Röhrig UF, Majjigapu SR, Chambon M, et al. Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors. Eur J Med Chem 2014;84:284–301.
   PubMed Web of Science ®Google Scholar
• Röhrig UF, Majjigapu SR, Vogel P, et al. Challenges in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors. J Med Chem 2015;58:9421–37.
   PubMed Web of Science ®Google Scholar
• Lang RW, Wenk PF. Synthesis of selectively trifluoromethylated pyridine derivatives as potential antihypertensives. Helv Chim Acta 1988;71:596–601.
   Web of Science ®Google Scholar
• Yu CJ, Zheng MF, Kuang CX, et al. Oren-gedoku-to and its constituents with therapeutic potential in Alzheimer’s disease inhibit indoleamine 2, 3-dioxygenase activity in vitro. J Alzheimers Dis 2010;22:257–66.
   PubMed Web of Science ®Google Scholar
• Yang S, Li X, Hu F, et al. Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis Lung Cancer (LLC) tumor-bearing mice. J Med Chem 2013;56:8321–31.
   PubMed Web of Science ®Google Scholar